# Cytokinetics clinical trials: 41 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 41 trials with Cytokinetics as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Cytokinetics: 41 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/cytokinetics

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 41
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 41, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| January 27, 2025 | NCT06793371 | AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF | Cytokinetics | Phase 2 | Recruiting | Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06793371) |
| December 16, 2024 | NCT06736574 | Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | Cytokinetics | Phase 3 | Recruiting | Heart Failure, Heart Failure With Reduced Ejection Fraction | 1,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06736574) |
| May 14, 2024 | NCT06412666 | A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). | Cytokinetics | Phase 2/3 | Active not recruiting | Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06412666) |
| October 13, 2023 | NCT06081894 | A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic... | Cytokinetics | Phase 3 | Active not recruiting | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06081894) |
| June 29, 2023 | NCT05924815 | Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval | Cytokinetics | Phase 1 | Completed | Healthy Participants | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05924815) |
| May 26, 2023 | NCT05877053 | A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants | Cytokinetics | Phase 1 | Completed | Healthy Participants | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05877053) |
| March 14, 2023 | NCT05767346 | Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM | Cytokinetics | Phase 3 | Completed | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 175 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05767346) |
| December 22, 2022 | NCT05662215 | A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants | Cytokinetics | Phase 1 | Terminated | Healthy Participants | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05662215) |
| July 5, 2022 | NCT05442775 | A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) | Cytokinetics | Phase 3 | Terminated | Amyotrophic Lateral Sclerosis | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05442775) |
| January 11, 2022 | NCT05186818 | Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM | Cytokinetics | Phase 3 | Completed | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 282 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05186818) |
| June 30, 2021 | NCT04944784 | A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) | Cytokinetics | Phase 3 | Terminated | Amyotrophic Lateral Sclerosis | 489 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04944784) |
| April 19, 2021 | NCT04848506 | Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM | Cytokinetics | Phase 2/3 | Enrolling by invitation | Symptomatic Hypertrophic Cardiomyopathy (HCM) | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04848506) |
| July 9, 2020 | NCT04464525 | Omecamtiv Mecarbil Post-trial Access Study | Cytokinetics | Phase 3 | Withdrawn | Chronic Heart Failure With Reduced Ejection Fraction | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04464525) |
| January 7, 2020 | NCT04219826 | Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic... | Cytokinetics | Phase 2 | Completed | Hypertrophic Cardiomyopathy (HCM) | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04219826) |
| November 25, 2019 | NCT04175808 | Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults | Cytokinetics | Phase 1 | Completed | QT Intervals Changes, QTc Intervals Changes | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04175808) |
| December 7, 2018 | NCT03767855 | A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects | Cytokinetics | Phase 1 | Completed | Symptomatic Obstructive Hypertrophic Cardiomyopathy, Healthy Subjects | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03767855) |
| November 30, 2018 | NCT03759392 | Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure | Cytokinetics | Phase 3 | Completed | Heart Failure With Reduced Ejection Fraction | 276 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03759392) |
| May 19, 2017 | NCT03160898 | A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Cytokinetics | Phase 2 | Completed | Amyotrophic Lateral Sclerosis | 458 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03160898) |
| October 18, 2016 | NCT02936635 | A Study for Patients Who Completed VITALITY-ALS (CY 4031) | Cytokinetics | Phase 3 | Completed | Amyotrophic Lateral Sclerosis (ALS) | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02936635) |
| October 11, 2016 | NCT02929329 | Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction | Cytokinetics | Phase 3 | Completed | Heart Failure | 8,256 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02929329) |
| March 1, 2016 | NCT02695420 | Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction | Cytokinetics | Phase 2 | Completed | Heart Failure With Reduced Ejection Fraction | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02695420) |
| January 1, 2016 | NCT02644668 | A Study of CK-2127107 in Patients With Spinal Muscular Atrophy | Cytokinetics | Phase 2 | Completed | Spinal Muscular Atrophy | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02644668) |
| November 10, 2015 | NCT02601001 | Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults | Cytokinetics | Phase 1 | Completed | Healthy Volunteer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02601001) |
| July 14, 2015 | NCT02496767 | Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year | Cytokinetics | Phase 3 | Completed | Amyotrophic Lateral Sclerosis | 744 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02496767) |
| February 8, 2013 | NCT01786512 | COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure | Cytokinetics | Phase 2 | Completed | Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction, Chronic Heart Failure, History of Chronic... | 544 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01786512) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 9 |
| Phase 1/2 | 1 |
| Phase 2 | 18 |
| Phase 2/3 | 2 |
| Phase 3 | 11 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 28 |
| Terminated | 6 |
| Recruiting | 2 |
| Withdrawn | 2 |
| Active not recruiting | 2 |
| Enrolling by invitation | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Heart Failure | 13 |
| Amyotrophic Lateral Sclerosis | 9 |
| Cardiomyopathy, Hypertrophic | 5 |
| Ventricular Dysfunction, Left | 2 |
| Lymphoma, Non-Hodgkin | 1 |
| Hodgkin Disease | 1 |
| Intermittent Claudication | 1 |
| Peripheral Arterial Disease | 1 |
| Breast Neoplasms | 1 |
| Myasthenia Gravis | 1 |
| Myocardial Ischemia | 1 |
| Angina Pectoris | 1 |
| Muscular Atrophy, Spinal | 1 |
| Dyspnea | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Car manufacturers in the United States](https://specstream.ai/data/businesses/car-manufacturers/united-states)
- [Mental health clinics in the United States](https://specstream.ai/data/businesses/mental-health-clinics/united-states)
- [Appraisers in the United States](https://specstream.ai/data/businesses/appraisers/united-states)
- [Honduran restaurants in the United States](https://specstream.ai/data/businesses/honduran-restaurants/united-states)
- [Temp agencies in the United States](https://specstream.ai/data/businesses/temp-agencies/united-states)
- [Elementary schools in the United States](https://specstream.ai/data/businesses/elementary-schools/united-states)
